A Patient Guide to Understanding Stage 2 Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of blood cancer that affects the bone marrow and blood-forming cells. In CML, a genetic change called the Philadelphia chromosome leads to the production of an abnormal protein called BCR-ABL1, which causes white blood cells to grow uncontrollably. Stage 2 CML, often referred to as the accelerated phase, means the disease is progressing faster than in the initial chronic phase but has not yet reached the blast phase, which resembles acute leukemia.

Symptoms may include fatigue, unexplained weight loss, night sweats, easy bruising or bleeding, and fullness in the upper abdomen due to an enlarged spleen. However, some patients may not have noticeable symptoms, and CML is sometimes discovered during routine blood tests.

Understanding your diagnosis is the first step in actively participating in your care. Each patient’s experience with CML can differ, and your oncologist will tailor your treatment plan based on your blood counts, genetic testing, and overall health.

How someone can be diagnosed with Stage 2 CML

Diagnosing CML involves several steps:

1. Blood tests: Complete blood counts often show elevated white blood cells and may indicate anemia or low platelets.
2. Bone marrow biopsy: This test examines bone marrow cells to confirm the presence of CML and determine the proportion of immature cells (blasts).
3. Genetic and molecular testing: Detection of the Philadelphia chromosome or BCR-ABL1 gene confirms the diagnosis.
4. Imaging: In some cases, ultrasound or CT scans assess spleen or liver enlargement.

Your oncologist will monitor these tests over time to evaluate treatment response and adjust therapy as needed.

Treatment options for stage 2 CML

Treatment for stage 2 (accelerated phase) CML is designed to control disease progression, reduce abnormal white blood cells and prevent complications. Common options include:

1. Tyrosine kinase inhibitors (TKIs)

• Drugs such as TKIs target the BCR-ABL1 protein and slow cancer cell growth.
• TKIs are usually the first-line therapy, and many patients can achieve remission with consistent treatment.

In a previous interview with CURE, Dr. Jorge E. Cortes, of the Georgia Cancer Center, said: “When TKIs became available, they completely changed the history of CML and, in many ways, the history of cancer. They ushered in the era of targeted therapies that are more effective, better tolerated, and transformative in altering the natural course of the disease.”

1. Chemotherapy

• In cases where TKIs are insufficient or disease progresses rapidly, chemotherapy may be used to reduce the number of leukemic cells.

1. Allogeneic stem cell transplant

• Reserved for patients with high-risk disease or those who do not respond to TKIs.
• This approach replaces diseased bone marrow with healthy donor marrow and can offer a potential cure but carries significant risks.

1. Clinical trials

• Emerging therapies and combination treatments may be available in clinical trials, especially for patients who do not respond fully to standard therapy.

Side effects of stage 2 CML treatment

Each treatment carries potential side effects, which can vary depending on the specific therapy:

• TKIs: Fatigue, nausea, diarrhea, muscle cramps, skin rashes, fluid retention and liver enzyme changes.
• Chemotherapy: Low blood counts, increased infection risk, hair loss, nausea and fatigue.
• Stem cell transplant: Risk of infections, graft-versus-host disease, organ complications and prolonged recovery.

Your care team will monitor for side effects and may adjust dosages or provide supportive treatments to maintain quality of life.

What you should know

A stage 2 CML diagnosis can feel overwhelming, but effective treatments are available. Advances in targeted therapy, particularly TKIs, have transformed CML into a manageable condition for many patients. Active communication with your oncologist is essential to understand your treatment options, manage side effects and monitor disease progression.

Questions you might consider asking your oncologist include:

• What is the goal of my treatment at this stage?
• How will we monitor my response to therapy?
• Are there lifestyle changes or supportive care strategies that can help me feel better during treatment?
• When should we consider alternative treatments or clinical trials?

Engaging in ongoing conversations with your care team empowers you to make informed decisions and ensures your treatment plan aligns with your personal health goals.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

Reference

1. "How Targeted Therapies Are Transforming Chronic Myeloid Leukemia Care," by Ryan Scott. CURE; Nov, 19, 2025. https://www.curetoday.com/view/how-targeted-therapies-are-transforming-chronic-myeloid-leukemia-care

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.